AbbVie reported that etentamig met the main goal of its Phase 3 trial in multiple myeloma, improving progression-free outcomes versus standard regimens at an interim checkpoint. The bispecific antibody is designed to bind tumor cells and T cells, aiming to generate an immune response against disease in patients who progressed on multiple lines. AbbVie also highlighted a safety profile with lower rates of serious immune responses commonly associated with bispecifics, including cytokine release syndrome and ICANS—an area that often dictates monitoring intensity and feasible treatment settings. The company’s interim monitoring and subsequent unblinding signal a clear efficacy signal early in the readout process, positioning etentamig as a potential next-generation option in a crowded bispecific landscape.